Towards a sane and rational approach to management of Influenza H1N1 2009 by Gallaher, William R
BioMed  Central
Page 1 of 7
(page number not for citation purposes)
Virology Journal
Open Access Commentary
Towards a sane and rational approach to management of Influenza 
H1N1 2009
William R Gallaher
Address: Department of Microbiology, Immunology and Parasitology, Louisiana State University Health Sciences Center, 1901 Perdido Street, 
New Orleans, Louisiana 70112, USA
Email: William R Gallaher - billg35445@yahoo.com
Abstract
Beginning in March 2009, an outbreak of influenza in North America was found to be caused by a
new strain of influenza virus, designated Influenza H1N1 2009, which is a reassortant of swine, avian
and human influenza viruses. Over a thousand total cases were identified with the first month,
chiefly in the United States and Mexico, but also involving several European countries. Actions
concerning Influenza H1N1 2009 need to be based on fact and science, following recommendations
of public health officials, and not fueled by political, legal or other interests. Every influenza
outbreak or pandemic is unique, so the facts of each one must be studied before an appropriate
response can be developed. While reports are preliminary, through the first 4 weeks of the
outbreak it does not appear to be severe either in terms of the attack rate in communities or in
the virulence of the virus itself. However, there are significant changes in both the hemagglutinin
and neuraminidase proteins of the new virus, 27.2% and 18.2% of the amino acid sequence, from
prior H1N1 isolates in 2008 and the current vaccine. Such a degree of change qualifies as an
"antigenic shift", even while the virus remains in the H1N1 family of influenza viruses, and may give
influenza H1N1 2009 significant pandemic potential. Perhaps balancing this shift, the novel virus
retains more of the core influenza proteins from animal strains than successful human influenza
viruses, and may be inhibited from its maximum potential until further reassortment or mutation
better adapts it to multiplication in humans. While contact and respiratory precautions such as
frequent handwashing will slow the virus through the human population, it is likely that
development of a new influenza vaccine tailored to this novel Influenza H1N1 2009 strain will be
essential to blunt its ultimate pandemic impact.
Introduction
On April 9, 2009 it became apparent to public health offi-
cials in Mexico City that an outbreak of influenza was in
progress late in the influenza season [1]. On April 17, two
cases in children were also reported in California near the
Mexican border [2]. Virus samples were obtained and the
virus determined to be a novel strain of influenza A of the
H1N1 serotype. Preliminary tests conducted by the Cent-
ers for Disease Control and Prevention (CDC) indicated
that the virus was a novel reassortant, containing genetic
elements of influenza viruses found in swine, birds and
human beings.
Influenza virus, an enveloped virus of the Orthomyxoviri-
dae family, has a unique capacity for genetic variation that
is based in two molecular features of the virus family [3].
First of all, the surface proteins of the virus are highly var-
iable, able to mutate up to 50% of their amino acid
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sequence and still perform their functions in infection.
Secondly, the viral genome is segmented, with eight RNA
segments that are genetically independent of one another.
In a mixed infection of different influenza genotypes,
these segments can almost randomly reassort resulting in
hybrid genotypes with some segments derived from one
virus strain, while the other segments are derived from a
second strain.
Less than one month later, hundreds of probable cases of
infection by this novel virus, designated Influenza H1N1
2009, had been identified, with 26 deaths, centered about
the area of Mexico City. An additional several hundred
probable cases had been identified in the United States
[4], most associated with recent travel to Mexico, and con-
centrated in California, Texas and New York. Sporadic
cases, also associated with travel to Mexico in large part,
were found in several European countries as well. The
World Health Organization (WHO) began to declare ever
higher stages on its "pandemic" scale, designating the
novel Influenza H1N1 2009 a potential threat to world-
wide health [5]. Press coverage and involvement of public
officials in the response to the novel virus has reached epic
proportions.
This commentary is intended to review and analyze the
salient facts of the outbreak and the molecular sequence
of the principal external antigens of Influenza H1N1
2009. The discussion will focus on the implications of this
analysis for the continued course of the outbreak and the
medical response.
Discussion
Tenor of the Response to Influenza H1N1 2009
Actions concerning Flu H1N1 2009 need to be based on
fact and science, following recommendations of public
health officials, and not fueled by political, legal or media
interests and hysteria. This is time for calm, thoughtful
action, and not the panic we have seen spread around the
globe inspired by media reports. When 10 schools or an
entire school district are closed due to one suspected case
of influenza, we might well ask if our response has been
measured and appropriate. The good faith of the public is
a precious commodity. When one day a pandemic is
trumpeted, and the next day the outbreak is called no
more than normal flu and under control, and then a call
goes out for a multibillion dollar vaccine program to
defend against a major pandemic, one risks the public
feeling whiplash and the credibility of public officials
being damaged. Further, every measure of response has a
cost-benefit ratio that needs to be carefully considered,
which is best done in collaboration with public health
professionals. We have seen unnecessary and useless quar-
antines, interdictions of trade and excessive closures
which cannot be sustained and have little if any benefit.
Travel in and out of Mexico has been severely disrupted,
but not to New York City which also has many confirmed
cases. A cruise ship plies the Pacific, avoiding Mexican
ports with little or no influenza activity, but plans to host
its passengers an extra night in San Diego, with a higher
number of H1N1 cases in the area than most areas of Mex-
ico. At some point in what will probably be a long engage-
ment with this new influenza strain, a more precisely
targeted and rational response will be needed.
The Enigma of Response and Responsibility
Every influenza outbreak or pandemic is unique, so the
facts of each one must be studied before an appropriate
response can be developed [3]. No actual pandemic
matches the theoretical influenza pandemic or past his-
tory. Each must be judged on its own evolution. The only
really accurate assessments have been retrospective, after
years or decades of further analysis, so it is important for
both the scientific and general public to understand that
decisions will need to be made using the best information
available at the time and will be fallible. There can be no
standard playbook. However, fallible does not mean irra-
tional. Even though elected and corporate officials are
charged with the responsibility to make such decisions,
and no one wishes to be found negligent in retrospect, the
best course is to closely follow the recommendations of
recognized experts in the field of influenza virology and
public health who have made the study and understand-
ing of this viral disease their life's work. The WHO, CDC,
academic virologists and physicians, and state epidemiol-
ogists know their business and should be trusted to guide
public policy. An elected official cannot and should not
try to reproduce and override, with an hour's briefing,
their cumulative decades of experience. This is no time to
haul out tired agendas concerning immunization or
immigration or cultural and ethnic biases, using influenza
for cover.
Nature of the Outbreak to Date
This virus constitutes a serious threat not based on the
outbreak thus far, which has been, in historical terms, very
limited in the total number of probable cases, but rather
on the potential of the virus. To date, influenza H1N1
2009 has not made a very successful penetrance into the
human population. Even if 22,000 in Mexico City were
infected, a high estimate, it would constitute only 0.1% of
the population of 22 million – one of the more populous
metropolitan areas on earth. In contrast, in a "normal"
influenza season, with an "ordinary" strain of influenza,
there are 200,000 cases and 36,000 deaths in only a few
months each winter in the United States alone [6]. Classic
pandemic flu attack rates are, unfortunately, far higher.
Indeed, influenza is in a class of its own for its potential
ability to infect enormous numbers of humans in a very
short period of time – thus far with H1N1 2009 we are notVirology Journal 2009, 6:51 http://www.virologyj.com/content/6/1/51
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even close to that level. This may technically be a "pan-
demic" in the sense of human-to-human virus transmis-
sion of a novel virus in more than one region of the
planet, but would not yet be recognizable as an influenza
pandemic to anyone who has lived through one.
There are two very separate meanings for "severity" when
discussing influenza. One relates to the virulence of the
virus in any given host; the other to the attack rate, or
numbers of cases of infection per unit of population.
Thus, one can have a "severe" pandemic, affecting mil-
lions of human beings, with a relatively avirulent – not
severe – influenza virus that results in relatively few hos-
pitalizations or deaths. On the other hand, one can have
a limited outbreak, such as Southeast Asia has experienced
in recent years with bird flu, with a highly virulent, severe
virus that produces very high percentages of hospitaliza-
tion and high mortality.
While it is very early to properly evaluate public health
reports and statistics, the Influenza H1N1 2009 outbreak
thus far does not appear to be severe in either respect.
However, within the viral genetic sequence there is at least
the potential for a severe pandemic. Also, an unusually
high number of cases appear to be in previously healthy
young adults, a feature found more commonly in the
more virulent influenza viruses.
Since influenza was first isolated in the 1930s, it has been
axiomatic that the severity of an epidemic or pandemic is
proportional to the susceptibility of the human popula-
tion, which is in turn directly related to the degree of
change in the surface proteins of the virus, the H and N
antigens [7]. The greater the change, the less that preexist-
ing human antibodies to influenza can neutralize the
virus, and the lower the "herd immunity" of the entire
human population. Minor incremental changes in these
antigens, denoted as "antigenic drift", lead to mild out-
breaks. Major, sudden changes in these antigens, denoted
as "antigenic shift", have led to the major pandemics of
influenza in the 20th century. There has not been a major
antigenic shift in human influenza since 1968.
Changes in the Hemagglutinin
The major component of influenza virus that determines
its epidemiological dynamic is the predominant surface
protein on the viral envelope, the H antigen. This protein
serves as the hemagglutinin or HA1 attachment protein. It
determines whether the virus is able to bind to and infect
cells of different species by its ability to attach to carbohy-
drate receptors on the cells. The protein loops that deter-
mine the sites of binding for antibody dominate the
immune response to the virus. Thus the H antigen is the
principal component of any influenza vaccine and the
efficacy of the vaccine is measurable by determining the
ability of the elicited antibodies to neutralize viral bind-
ing.
Figure 1 shows an amino acid sequence alignment of
Influenza H1N1 2009 with its predecessor HIN1 virus iso-
lated the previous year, in 2008, at Walter Reed Army Hos-
pital in Washington, DC. (The 2008 virus is in turn
identical in amino acid sequence to the H antigen in the
current influenza virus vaccine.) Each change in the
sequence of Influenza H1N1 2009 from the 2008 virus is
marked with an "X" in the alignment. It is obvious that
H1N1 2009 is significantly novel, 27.2% different from
the human H1N1 virus circulating in 2008 and the H anti-
gen in the current vaccine. Also noted in the figure are the
canonical sites for N-linked glycosylation of the protein,
at NxS/T motifs (underlined), as well as the approximate
positions of amino acids that determine the antigen spe-
cificity at five different protein loop regions on the surface
of the protein, designated Site A through Site E [8]. It is
obvious that the changes in amino acid sequence are con-
centrated in these antigenic sites. Additionally, one of the
sites, Site C, may be blocked by a novel N-linked glyco-
sylation at N277. All five of the known antigenic sites on
the protein are therefore unique, and so no human herd
immunity to this virus is to be expected anywhere in the
human population of 6.77 billion persons. This consti-
tutes a major antigenic shift which has in the past been the
basis of major human pandemics.
Additional sequence comparison (not shown) indicates
that, as stated by others in the press several times, Influ-
enza H1N1 2009 is not similar to the 1918 pandemic
influenza virus (18% different), and not similar to the
1976 swine flu from Ft. Dix, New Jersey (12% different).
Also, the amino acids most critical in specifying receptor
usage [9], indicated in the sequence alignment by aster-
isks, are identical to current human H1N1. Thus the spec-
trum of human infection in the respiratory tract is not
likely to be unusual relative to the 2008 H1N1 or other
recent influenza strains. These are positive features of the
virus arguing for a lower level of virulence.
Changes in the Neuraminidase
The second external protein of influenza virus, constitut-
ing 20–25% of the surface proteins, is the N antigen. This
protein is an enzyme named neuraminidase for its ability
to cleave neuraminic or sialic acid from complex carbohy-
drates such as mucins. In infection it serves to allow
release of newly produced virus from surface receptors
and to digest mucous secretions, allowing the virus better
access to the surface of susceptible cells and spread
through the respiratory tract. Its value as a spreading factor
is underscored by the fact that the currently licensed anti-
viral drugs oseltamivir (Tamiflu) and zanamivir (Relenza)
function as neuraminidase inhibitors. In the absence ofVirology Journal 2009, 6:51 http://www.virologyj.com/content/6/1/51
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Amino acid sequence alignment of the mature hemagglutinin (H) proteins of Influenza H1N1 2009 and its predecessor H1N1  isolated in 2008 Figure 1
Amino acid sequence alignment of the mature hemagglutinin (H) proteins of Influenza H1N1 2009 and its 
predecessor H1N1 isolated in 2008. The amino acid sequence of the H protein shown for the Influenza H1N1 2009 virus 
is derived from the segment 4 sequence of the isolate A/California/08/2009(H1N1) submitted from the CDC by Shu et al. on 
April 29, 2009, as Genbank FJ971076.  The sequence for Influenza H1N1 2008 is derived from the segment 4 sequence of the 
isolate A/District of Columbia/WRAMC-1154048/2008(H1N1) submitted from Walter Reed Army Institute of Research by 
Houng et al., collected from a patient on February 1, 2008, as Genbank CY038770. Only the sequences of the mature proteins, 
after cleavage of the signal sequence, are shown. Standard single-letter abbreviations for the amino acids are used. The col-
linear sequences were hand-aligned and also confirmed by online use of ClustalW. Amino acid positions showing differences 
between the two sequences are denoted with an “X”. There are 89 differences in 327 positions, or 27.2%. The canonical sites 
for N-linked glycosylation are  underlined. Amino acid regions contributing to each of five antigenic sites are labeled Site A 
through Site E.
Hemagglutinin (Attachment) HA1
A/California/08/2009(H1N1)
A/USA/WRAMC-1154048/2008(H1N1)
DTLCIGYHANNSTDTVDTVLEKNVTVTHSVNLLEDKHNGKLCKLRGVAPL 50
  X                               XX      X X X
DTICIGYHANNSTDTVDTVLEKNVTVTHSVNLLENSHNGKLCLLKGIAPL
HLGKCNIAGWILGNPECESLSTASSWSYIVETPSSDNGTCYPGDFIDYEE 100
X  X XX           X XXXX       X XXX       X X
QLGNCSVAGWILGNPECELLISKESWSYIVEKPNPENGTCYPGHFADYEE
Site C         Site E
LREQLSSVSSFERFEIFPKTSSWPNHDSNKGVTAACPHAGAKSFYKNLIW 150
                   X      XXXX  X X X X XX   X  X
LREQLSSVSSFERFEIFPKESSWPNHTVT-GVSASCSHNGESSFYRNLLW
Site A
LVKKGNSYPKLSKSYINDKGKEVLVLWGIHHPSTSADQQSLYQNADAYVF 200
 XX XXX  X     X X X        X   XXXX  XX  XXXX   X
LTGKNGLYPNLSKSYANNKEKEVLVLWGVHHPPNIGDQKALYHTENAYVS
Site B  * Site B
VGSSRYSKKFKPEIAIRPKVRDQEGRMNYYWTLVEPGDKITFEATGNLVV 250
 X  X  X  X    X          X      X    X X   X   XX
VVSSHYSRKFTPEIAKRPKVRDQEGRINYYWTLLEPGDTIIFEANGNLIA
Site D   ** *
PRYAFAMERNAGSGIIISDTPVHDCNTTCQTPKGAINTSLPFQNIHPITI 300
      XX XX     X XX XXX XXX    X    X      X  X
PRYAFALSRGFGSGIINSNAPMDKCDAKCQTPQGAINSSLPFQNVHPVTI
Site C
GKCPKYVKSTKLRLATGLRNIPSIQSR 327
 X     X X   XX 
GECPKYVRSAKLRMVTGLRNIPSIQSRVirology Journal 2009, 6:51 http://www.virologyj.com/content/6/1/51
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herd immunity to the H antigen, partial protection can be
provided if the same or similar N antigen is retained. Eick-
hoff and Meiklejohn showed that the infection rate with
the H3N2 virus was reduced up to 50% in Air Force cadets
who had received the H2N2 vaccine, due to the shared N2
antigen remaining identical [10]. If the N1 antigen of the
2009 virus proved to be similar to that of 2008, even with
an antigenic shift in H, then some cross protection from
prior H1N1 infection or the 2008 vaccine might be
expected. Unfortunately, in the case of influenza H1N1
2009, the N1 antigen also is significantly novel, differing
by 18.2% from the 2008 H1N1 virus. While the antigenic
sites within the N antigen are less well defined (reviewed
in [11]), the pattern of changes in the N antigen of the
2009 virus (not shown) are not encouraging. No cross
protection is likely.
Implications from Sequence Changes in H1N1 2009
Overall, it is clear from the sequence alignments of the
Influenza H1N1 2009 virus that, even though this virus is
still basically in the family of H1N1 viruses, the sequence
changes indicate a significant antigenic shift in both sur-
face antigens. The last time such an antigenic shift
occurred in both H and N antigens was the 1957 Asian
H2N2 pandemic.
A factor present in 1957 was that there was serological evi-
dence that those over 60 years of age retained an anti-
H2N2 antibody response from prior exposure to the virus
before 1900 [12]. This blunted the effect of the 1957 pan-
demic in the elderly. This factor is not expected in the case
of H1N1 2009, since there is no evidence that a virus with
a similar antigenic profile has circulated in the human
population in over 100 years.
Neither Swine Nor Mexico Are to Blame
The outbreak is due to a rare recombination of influenza
gene segments from swine with avian and human influ-
enza. Once this one time event occurred, swine are not a
significant immediate source of the human version of
influenza H1N1 2009, and the virus cannot be acquired
from handling or eating pork. The consensus among virol-
ogists is that the actual natural host and ultimate source of
influenza variants is migratory waterfowl. [13]. The pro-
spective slaughter of pigs in Egypt, and the international
interdiction of imported pork, have no rational basis in
science or public health.
As for this being a "Mexican" virus, analysis of the H
sequence by BLAST [14] reveals that the closest relative to
the Influenza H1N1 2009 virus previously isolated is in
fact a virus 95% identical to it, from swine in Indiana in
2000 (e.g. A/Swine/Indiana/P12439/00 (H1N2)). Border
interdiction makes no sense when the H gene is All-Amer-
ican, having been in Indiana longer than the Head Coach
and most of those playing football for Notre Dame. Simi-
larly, the closest neuramindase sequence, 94% identical,
is one isolated in Britain and elsewhere in Europe in the
1990s (e.g. A/Swine/England/195852/92 (H1N1)). The
parts of the virus may well have been imported into Mex-
ico, and accidentally assembled the new influenza 2009
virus there, leading to emergence by pure happenstance.
Such emergence can happen anywhere. Retrospective
analysis revealed that the 1918 H1N1 virus, dubbed the
"Spanish" flu for decades, is likely to have arisen in the
United States [15]. Assigning blame or even a country of
origin for an emergent virus is a dubious exercise more
likely to reinforce cultural bias and prejudice, and ignite
non-cooperation, than to be helpful in controlling influ-
enza.
Factors Predisposing to Control of Influenza H1N1 2009
Two additional facts concerning the virus are positive.
First, while the most successful pandemic influenza
viruses have changed only the H and N antigens and
retained the same human core proteins of the virus, influ-
enza H1N1 2009 has several more components from ani-
mal flu strains than the H2N2 and H3N2 viruses of 1957
and 1968, respectively. This may make the 2009 virus less
compatible with effective replication in humans, which
may in turn be holding it back in its penetrance of the
human population. Second, the 2009 virus is sensitive to
the two neuraminidase inhibitors licensed as antiviral
drugs. A reasonable conclusion from these last two facts is
that there is no evidence at all that this is a bioterror event,
but rather a novel virus perpetrated by nature alone.
Immediate Prospects for Control
The outbreak appears to be waning or controlled at its ori-
gins and certainly not growing logarithmically or of truly
pandemic proportions. However, influenza exhibits
marked seasonal occurrence even in pandemic years. We
have reached the end of the classic flu season in the North-
ern Hemisphere, and not yet begun that season in the
Southern Hemisphere. The outbreak could wane even if
we were not doing everything right; indeed it could wane
even if we were doing everything wrong, simply because
that is what the flu does this time of year. Its true potential
may not be revealed until the onset of the flu season in the
Northern Hemisphere in October or November of 2009.
Further Evolution of the Virus Possible
The greatest instability of a novel human virus is when it
first enters the human population and is under very heavy
selective pressure in the environment of the human respi-
ratory tract. As the influenza season in the Northern Hem-
isphere ends, the virus could simmer for months and co-
circulate with the 2008 strains of influenza. While recom-
bination events in the human population have not been
documented, the virus could shed more genes from itsVirology Journal 2009, 6:51 http://www.virologyj.com/content/6/1/51
Page 6 of 7
(page number not for citation purposes)
animal sources, acquire more human influenza genes and
become better adapted to human replication and spread.
A virus with the new coat of H and N antigens, built onto
the core of prior successful human pandemic influenza
viruses, could be a threat exceeding anything we have seen
since 1918, given the great increase in human populations
over the last 50 years. Further reassortment of viral genes
in pigs are also possible [16]. Alternately, incremental
mutations in other genes of the virus may achieve the
same result of enhanced replication in humans without
further recombination. There is simply no way to tell
where H1N1 2009 will evolve. The only honest answer to
the question of how this outbreak will evolve over the
next 6 to 18 months is: "I don't know."
General Planning for a Long-Term Response
It is for the continued circulation of an enhanced H1N1
2009 that we should plan, and develop a vaccine based on
the novel H and N antigens. Given only a few months,
and a worldwide capacity of only about 500 million doses
of human vaccine using present methods, use of vaccine
and antivirals must be rational and carefully controlled.
Already there is evidence that Tamiflu is in high demand
disproportional to actual cases, indicating possible
attempts to either use the drug for prophylaxis or to horde
it for later use. If true pandemic attack rates are reached
later this year or next, there is risk that medical profession-
als would lose control of a valuable resource to treat the
ill. Recall that when only a few individuals received letters
laced with anthrax, the antibiotic ciprofloxacin became
scarce very quickly. Measures need to be taken to assure
that a similar scenario is not possible with the limited
amount of antivirals available.
Common sense preventive measures, such as frequent
handwashing and discretion on close personal human
contact, and carefully targeted school and worksite clo-
sures, will buy time and slow down the outbreak, until an
effective multi-year vaccine program can provide the best
prevention. While influenza virus can survive on inani-
mate surfaces, it is spread most easily by direct human
contact. Contact control among human beings, maintain-
ing literally an arm's length from others wherever practi-
cable, and staying home when sick, will achieve more
than all the antiseptic wipes and face masks that can be
manufactured. The CDC and WHO are actively promul-
gating behavioral changes that can reduce the circulation
of influenza [17]
Further education and preparation of health care workers
and first responders to deal with an influenza pandemic is
critical. Only a physician over 60 years of age was even in
medical school when the last and mildest influenza pan-
demic took place in 1968. Only a physician over 70 was
in medical school during the last pandemic when both the
H and N antigens exhibited significant change, with mas-
sive morbidity worldwide in 1957. Few working in virol-
ogy or the health field today know an influenza pandemic
except through the eyes of a child. If and when it happens,
it will change our entire frame of reference for epidemic
respiratory disease.
Future Strategies
There is also need for enhanced influenza research and
development. The priority of influenza waned in the
absence of a pandemic, coupled with the availability of
drugs and what seemed to be adequate vaccine technol-
ogy. However, the antivirals will never have been used to
the extent that is likely should this H1N1 2009 outbreak
continue. If resistance to these antivirals were to develop
due to their overuse and misuse, much as in the case of
antibiotics for bacteria, then there is currently no backup
drug to combat the virus. Antivirals that inhibit infection
and fusion have been developed for viruses such as
human immunodeficiency virus (HIV) [18] that have very
similar entry mechanisms, and should be developed for
influenza as well.
As for the influenza vaccine, it is still produced by rela-
tively archaic methods developed in the 1930s to 1950s
using mass quantities of embryonated chicken eggs. We
are not far beyond the pioneering days of Goodpasture,
Woodruff, Buddingh and Francis in this regard [19]. Each
dose of flu vaccine requires the use of 1.2 live eggs, or
about 600 million embryonated eggs to produce 500 mil-
lion does of virus for 6.77 billion people. The math is not
encouraging. Vaccines targeting viruses such as measles,
mumps, rubella and hepatitis B employ cell culture or
recombinant technologies and have superior safety char-
acteristics. Programs for greater efficiency in producing
effective and safe influenza vaccines have been too long
delayed in development and need to be implemented
quickly, to assure that this and future threats of pandemic
influenza can be met.
Over the long run, immunization provides the best pre-
ventive strategy against influenza virus. Critics revel in cit-
ing the 1976 swine flu vaccine, which produced 25
vaccine-associated deaths due to Guillain-Barre syndrome
while the virus itself only resulted in one death at Ft. Dix,
New Jersey. However, such vaccine-bashing ignores the
fact that this fatal complication occurred in only 1 in a
million vaccinees, and was not seen either before or since
that immunization campaign [3]. Many hundreds of mil-
lions of doses of trivalent H1, H3 and B influenza vaccine
have been administered over the intervening 30 years
without significant complications, while saving countless
lives.
As a patient with significant cardiopulmonary disability, I
have had clinical influenza three times in my life, in 1948,
1965 and 1974, and been hospitalized twice with second-Publish with BioMed Central    and   every 
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ary pneumococcal pneumonia. Since 1977 I have been
routinely administered the influenza vaccine, and not
only have I been free of influenza since then, but have
twice nursed a spouse to health through influenza. To
those critics of influenza immunization I can only say that
I am certain that I would choose immunization over the
disease, even at the risk of complications or the rare pos-
sibility of a vaccine-associated death. To be frank, when I
look at the changes in the H1N1 2009 hemagglutinin
from the 2008 virus, I see in them the face of my possible
executioner. If they need someone to be first in line to
receive the new H1N1 2009 vaccine, I hereby volunteer.
Overall, development of antiviral immunizations have
long been recognized as the most cost efficient use of pub-
lic dollars in the entire health field, both in lives saved and
economic impact.
Conclusion
Influenza H1N1 2009 is a novel virus quite unlike even
the other H1N1 influenza viruses that have preceded it as
agents of human influenza. The fact that its hemaggluti-
nin is 27.2% different and its neuraminidase is 18.2% dif-
ferent in amino acid sequence from the 2008 H1N1 and
vaccine virus strains give Influenza H1N1 2009 significant
pandemic potential, based on historical pandemics of the
20th century. However, it has yet to prove that potential in
what is an outbreak with low community attack rates and
modest virulence. Further evolution of the virus toward a
more efficient agent of human disease may yet enable it to
produce a major pandemic. The future course of the out-
break cannot be predicted, but prudence dictates that a
new influenza vaccine, targeted to the novel influenza
H1N1 2009 sequence be quickly developed and prepared
for worldwide administration. In the absence of existing
human "herd" immunity to this virus, only immunization
provides a significant hope of suppressing the long-term
impact of this newly emergent virus.
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